Response to letter entitled: Re: Pathologic Complete Responses, Long-term Outcomes, and Recurrence Patterns in HER2-low vs. HER2-zero Breast Cancer after Neoadjuvant Chemotherapy

Article Oncology

Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer

Paolo Tarantino et al.

Summary: This study investigated whether low ERBB2 expression is associated with distinct clinicopathologic characteristics and prognosis among patients with hormone receptor-positive and triple-negative breast cancer. The results did not support the interpretation of ERBB2-low breast cancer as a distinct biologic subtype. ERBB2-low expression was positively associated with the level of ER expression, suggesting confounding effects in prognostic analyses of ERBB2-low expression.

JAMA ONCOLOGY (2022)

Add to Collection

Article Oncology

Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy

Sora Kang et al.

Summary: This study investigated the clinical outcomes and relapse patterns of HER2-low or-zero breast cancer patients in an Asian population. The study found that HER2-low breast cancer patients had higher hormone receptor positivity and higher 5-year overall survival and disease-free survival rates. However, there were no significant differences in pathological complete response rate and prognosis based on HER2 status in HER2-low breast cancer patients.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Article Oncology

Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials

Carsten Denkert et al.

Summary: The development of anti-HER2 antibody-drug conjugates provides new therapeutic options for breast cancer patients, including those with low expression of HER2. HER2-low-positive breast cancer is a distinct subtype with specific biology, showing differences in response to therapy and prognosis, especially in hormone receptor-negative tumors.

LANCET ONCOLOGY (2021)

Add to Collection

Review Oncology